

# TABLE OF CONTENTS

<b>Oncologic Care I.....</b>	<b>1</b>	<b>Oncologic Care III.....</b>	<b>103</b>		
Oncologic Care I Panel .....	3	Oncologic Care III Panel .....	105		
<b>Cancer Screening and Prevention</b>					
By Lisa M. Holle, Pharm.D., FHOPA, BCOP					
Introduction .....	7	Introduction .....	109		
Cancer Prevention .....	9	Common Physical and Psychosocial Problems .....	110		
Cancer Screening .....	14	Cardiac Toxicities .....	111		
References .....	23	Chemotherapy-Induced Peripheral Neuropathy .....	112		
Self-Assessment Questions .....	27	Cancer-Associated Cognitive Changes .....	114		
<b>Lung Cancer</b>					
By Sara K. Butler, Pharm.D., BCPS, BCOP					
Introduction .....	31	Sleep Disorders .....	116		
Small Cell Lung Cancer .....	33	Sexual Health .....	117		
Treatment of SCLC .....	33	Preventive Health .....	118		
Classification of NSCLC .....	34	Overall Approach .....	119		
NSCLC Treatment of Early-Stage Disease .....	35	Conclusion .....	121		
NSCLC Treatment of Unresectable or Locally Advanced Stage III .....	37	References .....	124		
NSCLC Treatment of Recurrent or Metastatic Disease .....	37	Self-Assessment Questions .....	128		
NSCLC Metastatic Disease Second-line Therapy .....	42	<b>Vaccination in the Patient with Immunocompromise</b>			
Future Directions .....	44	By Kamakshi V. Rao, Pharm.D., FASHP, BCOP, CPP			
References .....	44	Background and Definitions .....	133		
Self-Assessment Questions .....	47	Immunization Basics .....	134		
<b>Oncologic Care II.....</b>	<b>51</b>	Scope of the Issue .....	135		
Oncologic Care II Panel .....	53	Data and Recommendations .....	135		
<b>Toxities of Oral Targeted Chemotherapy</b>					
By Lisa K. Lohr, Pharm.D., BCPS, BCOP					
Introduction .....	57	Conclusion .....	143		
Dermatologic Adverse Effects from Oral Targeted Chemotherapy .....	58	References .....	143		
Cardiac Adverse Effects from Oral Targeted Chemotherapy .....	63	Self-Assessment Questions .....	146		
Metabolic Adverse Effects from Oral Targeted Chemotherapy .....	71	<b>Hematologic Care I.....</b>			
Conclusion .....	76	By Sol Atienza Yoder, Pharm.D., BCOP			
References .....	77	Overview of Chronic Lymphocytic Leukemia .....	157		
Self-Assessment Questions .....	79	Newer Drugs .....	160		
<b>Melanoma</b>					
By LeAnn B. Norris, Pharm.D., FCCP, BCPS, BCOP					
Introduction .....	83	Future Therapies .....	164		
Pathophysiology .....	84	Complications of CLL and Management .....	166		
Screening and Prevention .....	85	Conclusion .....	174		
Diagnosis and Prognosis .....	85	References .....	175		
Treatment .....	87	Self-Assessment Questions .....	179		
Metastatic Disease Treatment .....	89	<b>Chronic Lymphocytic Leukemia</b>			
Treatment Decisions .....	93	By Sol Atienza Yoder, Pharm.D., BCOP			
Monitoring .....	93	Overview of Chronic Lymphocytic Leukemia .....	157		
Conclusion .....	95	Newer Drugs .....	160		
References .....	96	Future Therapies .....	164		
Self-Assessment Questions .....	98	Complications of CLL and Management .....	166		
<b>Multiple Myeloma</b>					
By Houry Leblebjian, Pharm.D., BCOP					
Introduction .....	183	Conclusion .....	174		
Clinical Presentation .....	184	References .....	175		
Diagnosis and Staging .....	185	Self-Assessment Questions .....	179		
Response Criteria .....	186	<b>Hematologic Care I.....</b>			
Treatment Overview .....	186	By Sol Atienza Yoder, Pharm.D., BCOP			
New Therapies for R/R MM .....	198	Overview of Chronic Lymphocytic Leukemia .....	157		
Supportive Care .....	200	Newer Drugs .....	160		
Conclusion .....	202	Future Therapies .....	164		
References .....	203	Complications of CLL and Management .....	166		
Self-Assessment Questions .....	206	Conclusion .....	174		